NASDAQ:BOLT

Bolt Biotherapeutics . Stock Insider Trading

Healthcare > Biotechnology

Buy BOLT

*Your capital is at risk

$4.63

-0.480 (-9.39%)

At Close: Jun 03, 2026

Bolt Biotherapeutics . Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -75.46. In total, the insiders bought 280.33K and sold 134.07K BOLT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-75.46
● Buy	280.33K shares
● Sell	134.07K shares
55% Buy Activity Moderate Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 12, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Nemec Sarah Senior Vp, Finance And Pao	Officer	1 236 Value: $7K
Dec 12, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Nemec Sarah Senior Vp, Finance And Pao	Officer	1 589 Value: $9K
Dec 12, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Nemec Sarah Senior Vp, Finance And Pao	Officer	2 199 Value: $12.0K
Dec 12, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Nemec Sarah Senior Vp, Finance And Pao	Officer	2 499 Value: $13.6K
Dec 12, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Nemec Sarah Senior Vp, Finance And Pao	Officer	4 499 Value: $24.5K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	O'callaghan Brian Director	Director	1 100 Value: $7K
Dec 12, 2025 Buy	Director Stock Option (Right to Buy) A-Award	O'callaghan Brian Director	Director	1 100 Value: $6K
Dec 12, 2025 Buy	Director Stock Option (Right to Buy) A-Award	O'callaghan Brian Director	Director	1 250 Value: $7K
Dec 12, 2025 Buy	Director Stock Option (Right to Buy) A-Award	O'callaghan Brian Director	Director	1 393 Value: $8K
Dec 12, 2025 Buy	Director Stock Option (Right to Buy) A-Award	O'callaghan Brian Director	Director	1 810 Value: $10K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Laporte Kathleen Director	Director	1 100 Value: $16.9K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Laporte Kathleen Director	Director	1 250 Value: $40.8K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Laporte Kathleen Director	Director	1 250 Value: $34.0K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Berner Laura Director	Director	1 100 Value: $7K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Berner Laura Director	Director	1 250 Value: $40.8K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Berner Laura Director	Director	1 100 Value: $16.9K
Dec 12, 2025 Buy	Director Stock Option (Right to Buy) A-Award	Berner Laura Director	Director	613 Value: $3K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Onetto Nicole Director	Director	1 250 Value: $40.8K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Onetto Nicole Director	Director	1 250 Value: $49.8K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Onetto Nicole Director	Director	611 Value: $37.0K
Dec 12, 2025 Buy	Director Stock Option (Right to Buy) A-Award	Onetto Nicole Director	Director	1 100 Value: $6K
Dec 12, 2025 Buy	Director Stock Option (Right to Buy) A-Award	Onetto Nicole Director	Director	1 100 Value: $6K
Dec 12, 2025 Buy	Director Stock Option (Right to Buy) A-Award	Onetto Nicole Director	Director	1 107 Value: $6K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Dupont Jakob Director	Director	1 000 Value: $7K
Dec 12, 2025 Sell	Director Stock Option (Right to Buy) D-Return	Dupont Jakob Director	Director	1 100 Value: $7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BOLT BIOTHERAPEUTICS, INC.

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for col...

Read Full Profile Here